Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 4Active not recruiting 4Recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Recurrence 1Carcinoma in Situ 1

Interventions

Gemcitabine 10Docetaxel 5Mitomycin 4erdafitinib 3durvalumab 3Cystoscopy 3disitamab vedotin 2BCG Vaccine 25-aminolevulinic acid hexyl ester 2tremelimumab 1tislelizumab 1monalizumab 1dodecyl maltoside 1chondroitin sulfate, sodium hyaluronate drug combination 1bicalutamide 1Urine Specimen Collection 1Transurethral Resection of Bladder 1Therapeutic Uses 1Surveys and Questionnaires 1Saline Solution 1Patient Discharge 1Paclitaxel 1Nonsteroidal Anti-Androgens 1Monatide (IMS 3015) 1Mitozytrex 1Metformin 1Magnetic Resonance Spectroscopy 1Laser Therapy 1Hyaluronic Acid 1House Calls 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Non-Muscle Invasive Bladder Neoplasms × BCG Vaccine × Clear all
NCT06833073 2026-05-28

INTerpath-011

Merck Sharp & Dohme LLC

Phase 2 Recruiting
308 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT06187506 2024-07-12

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Fudan University

Phase 2 Recruiting
20 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡